Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors - Yahoo Finance
LOS ANGELES, October 06, 2021--(BUSINESS WIRE)--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Omeros investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/omeros-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration ("FDA") had identified deficiencies with the Company’s Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which "preclude discussion of labeling and post-marketing requirements/commitments at this time." Though the "FDA did not provide specific details of the deficiencies in its notification[,]" the Company stated that it "does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA)."
On this news, Omeros’s stock price fell $5.25 per share, or 38%, to close at $8.54 per share on October 1, 2021, thereby injuring investors.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice: Persons with non-public information regarding Omeros should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
source: https://finance.yahoo.com/news/glancy-prongay-murray-llp-leading-200000104.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.